Drugs / Pentixather
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05557708 | Jul 2026 → Jun 2028 expected | lung carcinoid tumor, small cell lung carcinoma | Yusuf Menda | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentixather | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05557708 ↗ |
| Route | Intravenous | “Single intravenous infusion of Pentixather radiolabeled with Lead-212.” NCT05557708 ↗ |
| Target | CXCR4 | “to target malignant cells with the CXCR4 ligand” NCT05557708 ↗ |